What services does JCC Group provide for pharmaceutical and biologics manufacturers?

JCC Group offers end-to-end regulatory consulting services for pharmaceutical and biologics companies, including 21 CFR Part 211 cGMP compliance, Quality Management System (QMS) design, validation strategy, FDA inspection readiness, supplier qualification, data integrity assessments, and harmonization with ICH international standards (Q7, Q8, Q9, Q10, and Q11). Our consultants partner with clients across the full product lifecycle — from facility start-up and clinical-stage manufacturing through commercial production and post-approval changes.

What types of companies does JCC Group work with?

We support a broad spectrum of clients, including emerging biotech startups, contract manufacturers (CMOs/CDMOs), mid-size pharmaceutical companies, global drug manufacturers, biologics and cell & gene therapy developers, and international manufacturers exporting to the U.S. market. Whether you are launching your first product or managing a multi-site global operation, our services scale to fit your needs.

What is 21 CFR Part 211, and who must comply?

21 CFR Part 211 establishes the FDA's Current Good Manufacturing Practice (cGMP) requirements for finished pharmaceuticals. It applies to any company involved in manufacturing, processing, packaging, labeling, or holding human and veterinary drug products distributed in the United States — including drug substance and drug product manufacturers, contract facilities, and repackagers.

How does JCC Group help companies achieve 21 CFR Part 211 compliance?

We provide comprehensive support including cGMP gap assessments, QMS design and implementation, SOP and documentation development, equipment qualification (IQ/OQ/PQ), process and cleaning validation, quality control laboratory compliance, change control programs, CAPA systems, and mock FDA inspections. Our team builds compliance programs tailored to your operations — not generic templates.

Does JCC Group support biologics manufacturers under 21 CFR Part 211?

Yes. While biologics are also governed by 21 CFR Part 600-series regulations, Part 211 still applies to many aspects of biologic drug product manufacturing. We support biologics manufacturers across monoclonal antibodies, recombinant proteins, vaccines, cell and gene therapies, and biosimilars — addressing both small-molecule and large-molecule complexities.

What are ICH guidelines, and why do they matter?

The International Council for Harmonisation (ICH) develops globally recognized standards for pharmaceutical quality, safety, and efficacy. Compliance with ICH guidelines — especially Q7 (API GMP), Q8 (Pharmaceutical Development), Q9 (Quality Risk Management), Q10 (Pharmaceutical Quality System), and Q11 (Drug Substance Development) — is essential for companies seeking global market access and harmonized regulatory approval across the U.S., EU, Japan, and other ICH regions.

How does JCC Group help companies align with ICH standards?

Our consultants integrate ICH principles into every aspect of our consulting work. We design Pharmaceutical Quality Systems aligned with ICH Q10, implement quality risk management frameworks per ICH Q9, support development activities under Q8/Q11, and ensure API manufacturing aligns with ICH Q7 — enabling clients to meet both FDA expectations and global harmonized requirements simultaneously.

Can JCC Group build a Quality Management System (QMS) from scratch?

Absolutely. We design and implement complete Quality Management Systems for new facilities, startups, and companies transitioning from clinical-stage to commercial manufacturing. Our QMS deliverables include Quality Manuals, SOPs, work instructions, forms, Master Production Records, Batch Production Records, change control systems, and integrated documentation control platforms.

Does JCC Group provide ongoing QMS maintenance and support?

Yes. Beyond initial implementation, we offer long-term advisory services to keep your QMS current with evolving regulations, support periodic management reviews, conduct internal audits, manage CAPA effectiveness checks, and provide regulatory intelligence updates. Many clients engage us as their long-term regulatory partner rather than a one-time consultant.

What happens during a mock FDA inspection conducted by JCC Group?

Our mock inspections replicate real FDA methodology — including facility walkthroughs, document reviews, employee interviews, and front-room/back-room dynamics. We assess your operations against 21 CFR Part 211, your QMS, and applicable ICH standards, then deliver a detailed report with prioritized findings, root cause insights, and clear remediation recommendations.

Can JCC Group help if we received a Form 483 or FDA Warning Letter?

Yes — rapid-response remediation is one of our core specialties. Our team conducts immediate root cause investigations, develops comprehensive CAPA plans, drafts written responses that meet FDA expectations, and manages the remediation process from start to finish. We have helped clients successfully close significant findings and restore compliance under tight deadlines.

Preparing and Submitting a GRAS Notification

For Nutraceutical Ingredients Marketed and Imported into the United States

A Comprehensive Service Guide by J&J Compliance Consulting Group (JJCC Group)

Understanding GRAS and the Regulatory Framework

“GRAS” stands for Generally Recognized As Safe. It is a determination, established under the Federal Food, Drug, and Cosmetic Act (FD&C Act), that a substance added to food is recognized by qualified experts as safe under the conditions of its intended use. For the nutraceutical industry—supplements, functional foods, fortified beverages, botanical extracts, and novel bioactive ingredients—the GRAS pathway is the most common and efficient route to lawfully market an ingredient in the United States without a pre-market food additive petition.

Many companies casually refer to the program as “GRASS,” but the correct regulatory term is GRAS. Securing a defensible GRAS status protects your business from enforcement action, supports customer and retailer due-diligence requirements, and accelerates time-to-market. JJCC Group manages the entire lifecycle—from the initial safety strategy to a complete, submission-ready GRAS Notice filed with the FDA.

The Governing Regulations: 21 CFR by Industry

The GRAS concept is codified principally in Title 21 of the Code of Federal Regulations. The specific parts that apply depend on the product category and how the ingredient will be used. JJCC Group maps each ingredient to the correct regulatory basis before any work begins.

21 CFR Citation	Application
21 CFR Part 170, Subpart E (§§170.30, 170.203–170.285)	The core GRAS regulation. Defines GRAS criteria and establishes the voluntary GRAS Notification Program (the GRASN process) administered by CFSAN.
21 CFR Part 182 / 184 / 186	Lists of substances affirmed or recognized as GRAS for direct and indirect use in food. JJCC Group checks whether your ingredient is already listed or requires a new self-determination.
21 CFR Parts 210 & 211	cGMP for pharmaceuticals/drugs. Relevant when a nutraceutical makes structure/function vs. drug claims, or when an ingredient straddles the supplement–drug line.
21 CFR Part 111	cGMP for dietary supplements—manufacturing, packaging, labeling, and holding. Governs the finished supplement product even after an ingredient is GRAS.
21 CFR Part 117	cGMP and Preventive Controls for Human Food (under FSMA). Applies to functional foods and food/beverage finished products containing the GRAS ingredient.
21 CFR Part 1, Subpart H (§1.500+)	Foreign Supplier Verification Program (FSVP). Governs ingredients and finished products imported into the USA.
21 CFR Part 820 / ISO 13485	Quality System Regulation for medical devices—relevant only when a delivery format or combination product crosses into the device space.

GRAS Requirements Broken Down by Category

A common point of confusion is that GRAS applies to a single thing. In practice, the GRAS determination attaches to an ingredient used under defined conditions, while separate regulatory obligations attach to the nutraceutical category and to the finished product. JJCC Group addresses all three layers.

Nutraceuticals (the Product Category)

“Nutraceutical” is a marketing term, not a single FDA legal category. Depending on formulation and claims, your product is regulated either as a dietary supplement (under DSHEA and 21 CFR Part 111) or as a conventional/functional food (under 21 CFR Part 117). This classification drives whether an ingredient even needs GRAS status: food and beverage ingredients require GRAS or a food-additive approval, whereas dietary-supplement ingredients may instead require a New Dietary Ingredient (NDI) notification. JJCC Group performs the classification analysis first so you pursue the correct pathway.

Ingredients (the Substance Itself)

The GRAS determination is made for the specific substance—its identity, manufacturing process, specifications, and the levels and conditions of intended use. The same ingredient can be GRAS for one use and not another. Requirements include a full chemical and manufacturing characterization, a dietary-exposure (intake) assessment, and a comprehensive safety review demonstrating both technical evidence of safety and common knowledge of that evidence among qualified experts (the “common knowledge” element unique to GRAS).

Finished Products Imported into the USA

Finished nutraceutical products and bulk ingredients imported into the United States face additional layers: Foreign Supplier Verification Program (FSVP) obligations under 21 CFR Part 1 Subpart H, facility registration under the Bioterrorism Act, accurate labeling, and Prior Notice for imported food shipments. The GRAS status of the ingredient does not by itself clear customs—the importer must still satisfy these import controls. JJCC Group coordinates the GRAS dossier with the import-compliance file so the two reinforce each other.

Who Is Responsible for Preparing and Submitting the GRAS Notice?

Responsibility for a GRAS determination rests entirely with the company that wishes to market the ingredient—the FDA does not “approve” GRAS status. There are two lawful routes:

Self-determination (self-GRAS): The company convenes a panel of qualified experts, compiles the safety record, and concludes GRAS without notifying the FDA. This is legal but carries the highest enforcement risk and offers no FDA acknowledgment.
GRAS Notification (GRASN): The company—called the “notifier”—voluntarily submits a GRAS Notice to FDA’s Center for Food Safety and Applied Nutrition (CFSAN). FDA reviews it and, if satisfied, issues a “no questions” letter, which is the market-recognized gold standard of GRAS assurance.

The notifier is legally responsible, but the dossier is built by a multidisciplinary team: toxicologists, an independent GRAS expert panel, regulatory specialists, and (for imports) the U.S. agent and importer. JJCC Group serves as the regulatory project lead—assembling the team, drafting every section, convening the independent expert panel, and submitting the notice on the notifier’s behalf through FDA’s electronic portal.

What a GRAS Notice Includes:

FDA prescribes a seven-part structure for a GRAS Notice in 21 CFR 170.225–170.255. Below is each required part, what it must contain, and exactly how JJCC Group completes it for you.

Part 1

Signed Statements and Certification (§170.225)

Identifies the notifier, the substance, the conditions of use, and the statutory basis for GRAS, and includes the signed certification that the notice is complete and that data are available to FDA on request.

How JJCC Group helps: We draft the entire signed-statement package, confirm the correct statutory basis (scientific procedures vs. common use in food before 1958), prepare the certification language, and ensure the notifier’s authorized signatory and FSVP/U.S.-agent details are correct for imported substances.

Part 2

Identity, Method of Manufacture, Specifications, and Use (§170.230)

Provides the substance’s chemical identity, manufacturing process, food-grade specifications, and stability data, plus the precise conditions of intended use and consumer exposure levels.

How JJCC Group helps: We compile the chemistry and manufacturing characterization, align specifications with compendial standards (USP/FCC), validate the analytical methods, and document the cGMP manufacturing controls under Parts 111/117 that support a food-grade specification.

Part 3

Dietary Exposure (§170.235)

Estimates the cumulative dietary intake of the substance from all intended uses, typically using NHANES consumption data and conservative exposure modeling.

How JJCC Group helps: We build the estimated daily intake (EDI) model, account for background exposure and overlapping food categories, and produce a defensible margin-of-safety calculation that the expert panel can endorse.

Part 4

Self-Limiting Levels of Use (§170.240)

Where applicable, describes any organoleptic or functional factors that naturally limit how much of the substance can be used.

How JJCC Group helps: We assess and document self-limiting factors (taste, solubility, technical function) where they strengthen the safety narrative, and clearly state when none apply.

Part 5

Experience Based on Common Use in Food Before 1958 (§170.245)

Applies only when the GRAS basis is historical common use rather than scientific procedures; documents widespread, safe consumption before January 1, 1958.

How JJCC Group helps: We evaluate whether the pre-1958 pathway is viable for traditional botanicals and, if so, assemble the historical, ethnographic, and trade evidence required to support it.

Part 6

Narrative and Safety Data (§170.250)

The scientific heart of the notice: a comprehensive narrative integrating all pivotal toxicology, metabolism, and clinical data, and explaining why qualified experts would generally recognize the substance as safe.

How JJCC Group helps: We conduct the systematic literature review, design and commission any needed toxicology studies, author the integrated safety narrative, and convene an independent expert panel to reach and document a consensus GRAS conclusion.

Part 7

Supporting Data and Information / List of References (§170.255)

Compiles every study, report, and citation relied upon, organized so FDA reviewers can verify each safety claim.

How JJCC Group helps: We assemble the complete reference library, obtain full-text studies, prepare the data-availability index, and format the dossier to FDA’s electronic submission standards before filing on your behalf.

Why JJCC Group

J&J Compliance Consulting Group provides end-to-end cGMP regulatory consulting across the pharmaceutical, biotech, medical device, food, and nutraceutical industries. For GRAS work, our team integrates regulatory strategy, scientific writing, expert-panel management, and import compliance under one roof. We do not hand you a template—we deliver a complete, defensible, submission-ready GRAS Notice, manage FDA correspondence through the “no questions” letter, and align your manufacturing and import files (Parts 111, 117, and FSVP) so your GRAS status holds up under inspection and customer audit.

Gap analysis and pathway determination (GRAS vs. NDI vs. food additive).
Full authoring of all seven GRAS Notice parts to 21 CFR 170 standards.
Independent expert panel recruitment and consensus management.
Toxicology study design, exposure modeling, and literature review.
Electronic submission to CFSAN and management of all FDA correspondence.
Coordination of FSVP, facility registration, and import controls for products entering the USA.